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Abstract: Huntington’s disease (HD) is a neurodegenerative dementia with a well recognised genetic
cause. Alcohol misuse is a major environmental factor relevant to numerous neurological presenta-
tions, including HD. We explored the effects of alcohol intake on clinical features of HD by means
of data from the Enroll-HD, which is a global registry study. A retrospective observational study
making use of the Enroll-HD periodic dataset up to 2020 (in accordance with the Enroll-HD guide-
lines, encompassing 16,120 subjects with the HD gene (CAG expansion > 36), was carried out. This
included 180 sites in 21 countries. The study looked at the association of alcohol use with the clinical
presentation of HD, specifically looking into the age of first symptoms and HD severity. We also
describe a specific case with manifest HD, a participant in the Enroll-HD study, whereby the patient’s
obsessionality was central to her pattern of high alcohol intake and to her successful avoidance of
alcohol thereafter. A record of past problems with high alcohol intake was more common in the
group with manifest HD (9.0%, n = 1121) when compared with the pre-manifest carriers of the HD
genetic abnormality (2.3%, n = 339). Age at onset of symptoms was not significantly influenced by
current alcohol misuse, or past misuse. The severity of clinical impairments in HD was influenced by
alcohol. Patients who reported high alcohol intake in the past had a statistically significant increase
in motor impairments, by the Unified Huntington’s Disease Rating Scale total motor score (Kruskal–
Wallis, post hoc Dunn’s, p < 0.001), and a significantly higher burden of psychiatric symptoms by the
Problem Behaviours Assessment score (Kruskal–Wallis, post hoc Dunn’s, p < 0.01) compared with
those not reporting high alcohol use. However, the past alcohol group did not have a lower Mini
Mental State Examination score (Kruskal–Wallis, post hoc Dunn’s, p > 0.05) The first symptom of HD,
as determined by the assessing clinician, was more likely to be psychiatric disturbance in patients
currently misusing alcohol or those with prior history of alcohol misuse (55% and 31% respectively)
when compared with controls (5%). Individual case experience, such as that presented in this study,
shows that HD and alcohol, two major genetic and environmental contributors to neurodegeneration,
interact in producing clinical problems. However, the complexities of these interactions are difficult
to define, and may require larger studies dedicated to exploring the various factors in this interaction.
Keywords: Huntington’s disease; alcohol; neurodegeneration
1. Introduction
Huntington’s disease (HD) is a neurodegenerative disorder characterised by a triad
of abnormal movements, psychiatric symptoms and progressive cognitive impairment
or dementia [1]. Currently, the evidence for an effect of alcohol on HD presentation and
disease course is limited. Psychiatric and behavioural changes are the most common initial
symptoms in HD, with depression occurring in half of the population [2]. Irritability,
aggression and apathy are common features, with apathy being the best neuropsychiatric
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predictor of disease progression [3]. In addition to depression, psychosis and obsessive-
compulsive symptoms can also be present [4,5]. There is increasing evidence for the
role of alcohol consumption on HD onset [6]. However, it is uncertain whether alcohol
dependence is more common in the HD population [7]. A number of studies have suggested
a link between HD and higher prevalence of alcohol abuse [8–11], although Pflanz et al.
suggested a similar rates to the population [12]. In addition to rates of alcohol abuse, King
proposed that most drinkers started abusing alcohol before manifesting symptoms [13].
The relationship between ongoing alcohol misuse or of prior alcohol misuse and symptom
onset or course is still unclear. Psychiatric symptoms such as depression have previously
been shown to be more common in those patients who misuse alcohol [13].
Both acute and chronic high intake of alcohol use can contribute to motor dysfunction
and a decline in cognition in general [14]. Chronic alcohol use can lead to alcohol related
brain injury and dementia as well as the more defined Wernicke–Korsakoff’s syndrome [14].
The burden of alcohol misuse in patients with neurodegenerative dementia can ac-
centuate cognitive decline and in some studies has been shown to affect the initial clinical
presentation [15]. Our study looks into the influence both of past and current, ongoing high
alcohol intake use the clinical phenotype of patients with HD. In doing so, we explored both
a well-recognised environmental contributor to dementia syndromes and a well-defined
monogenetic factor contributing to neurodegenerative cognitive impairment.
2. Methods
Enroll-HD is an international observational study of HD with more than 16,000 sub-
jects at 180 sites in 21 countries. Most participants in Enroll-HD are diagnosed with HD but
others are subjects identified as having the HD gene expansion that leads to symptomatic
HD. The database also includes a minority of HD family members who are genetically
untested and other contacts, but these participants did not contribute to our analyses.
On the initial visit, participants are asked about medical and family histories as well
as substance use. Follow up visits record progression of motor, cognitive and psychiatric
symptoms. The presented study was a retrospective observational study, making use of
the Enroll-HD periodic dataset up to 2020 (in accordance with the Enroll-HD guidelines
https://www.enroll-hd.org/ accessed on 28 January 2021). This anonymized dataset was
stored in Microsoft Excel, Microsoft Corporation, Seattle, United States and subsequently
analysed in GraphPad Prism, GraphPad Software incorporated, California, United States.
Estimated age at onset of symptoms was determined by the clinician from the clinical
history. The profile of HD symptoms was documented by means of validated instruments,
in accordance with Enroll-HD procedures. The Unified Huntington’s Disease Ratings
Scale (UHDRS) total motor score was used for motor features [16], and the Mini Mental
State Examination (MMSE) for cognition [17]. The Problem Behaviours Assessment (PBA)
and its five subscores (depression, irritability, psychosis, apathy and executive function)
provided a quantitative measure for psychiatric burden [18]. The neuropsychiatric profile
of HD was further determined by referring to symptom onset data as determined by
the clinician.
Alcohol use was recorded as part of each Enroll-HD visit with participants being asked
if there was a history of ‘alcohol problems in the past’ and asked about current alcohol
consumption. Participants were grouped into controls (below 14 units a week), current high
users (greater than 30 units a week) and those with a history of alcohol problems (‘alcohol
problems in the past’). Participants whose data did not conform to these distinct categories
were not included in the analyses. The inclusion and exclusion of patients is summarised
in the Figure 1. Enroll-HD participants sign an informed consent at recruitment. All sites
followed local ethical guidelines and had local ethical committee approval for the recording
of patient data.
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Figure 1. (a) Unified Huntington’s Disease Ratings Scale (UHDRS) scores, a measure of motor 
impairment, are lower in the control patient group, when compared with those who reported 
alcohol problems in the past (Kruskal–Wallis, post hoc Dunn’s, p < 0.0001); (b) Mini Mental State 
Examination (MMSE) when used as a measure of cognition is not related to alcohol or past alcohol 
use (Kruskal–Wallis, post hoc Dunn’s, p > 1). p values <0.01 shown as ‘**’ and p < 0.001 as ‘***’. 
As for the PBA components of depression, irritability, psychosis, apathy and 
executive function, patients who had a prior history of alcohol abuse had higher scores 
(indicating greater burden) in all these domains when compared with the control group. 
Figure 1. (a) Unified Huntington’s Disease Ratings Scale (UHDRS) scores, a measure of motor impairment, are lower in
the control patient group, when compared with those who reported alcohol problems in the past (Kruskal–Wallis, post
hoc Dunn’s, p < 0.0001); (b) Mini Mental State Examination (MMSE) when used as a measure of cognition is not related to
alcohol or past alcohol use (Kruskal–Wallis, post hoc Dunn’s, p > 1). p values <0.01 shown as ‘**’ and p < 0.001 as ‘***’.
An illustrative case showing a distinctive relationship between alcohol and clinical
manifestations of HD is also described.
3. Results
3.1. Demographics
The Enroll-HD periodic dataset included 16,120 HD patients from Europe, the Ameri-
cas and Australasia; the majority were caucasian (n = 15,102). Patients were split 7393:8727
male to female; the mean education level (ISCED) was 3.6. ISCED level 3 is equivalent
to the completion of secondary education. The majority of HD patients presenting to
Enroll-HD clinics had manifest disease; 5173 were pre-manifest. Regardless of the earliest
symptom type, the onset of symptoms was at 45.2 years old, as judged by the clinician. In
comparison, the first visit was on average 3.5 years later (48.7 years), again implying that
more patients with manifest disease, than pre-manifest, were under follow up
The most frequently designated HD symptom defining onset of manifest HD was
motor (as defined by UHDRS, usually involuntary movement in the form of chorea, 52%).
The frequency of mixed (19%), psychiatric (21%) or cognitive (8%) symptoms as defining
the onset of manifest disease was lower. However, mean ages for the earliest symptoms in
the three categories of motor, cognitive and psychiatric were 59, 43, 50 years, respectively,
implying that clinicians have greater confidence in attributing motor symptoms to HD itself
while other features are more likely to be formulated as incidental or, perhaps, prodromal.
3.2. The Effect of Alcohol on Onset of Huntington’s Disease (HD)
The prevalence of current high alcohol use (greater than 30 units per week) in the
combined manifest and premanifest HD population was relatively small (3%, n = 222).
However, a much larger number of subjects reported having a problem with alcohol use in
the past (9%, n = 1460). A history of alcohol problems in the past was more common in the
manifest HD group (7.7%, n = 1121) when compared with the premanifest (2.3%, n = 339).
The overlap between those patients who currently had high alcohol use and those who
had previously reported having alcohol problems was small. The number of patients who
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were both using large amounts of alcohol at the time of assessment and reported alcohol
problems in the past was just 0.6% (n = 85).
Cumulatively, the frequency of recreational drug use within the HD population (12.0%,
n = 1962) was high. This figure encompasses all recreational substances other than alcohol
but is not readily subdivided by specific substance or prior/ongoing patterns of use.
Interestingly, the number of subjects using recreational substances other than alcohol was
split evenly between patients who had manifest symptoms (n = 1057) and those who are
pre-manifest (n = 905).
The age at onset of symptoms was similar in those who had a history of past alcohol
use and those who consumed high levels of alcohol at the time of the data collection. Those
who did not report drinking (average onset 43.2 years) had an onset of symptoms similar
to that in subjects with past alcohol problems (43.1) but somewhat younger than those
describing current high levels of alcohol consumption (45.6). Breaking down the age at
onset of HD into its underlying core symptoms modalities (motor, cognitive or psychiatric),
there was no correlation between past alcohol use and the age of onset of particular domain.
The first symptom identified in HD by the clinician seemed to vary, depending on
whether the patient has a history of alcohol misuse, or was currently misusing alcohol. The
proportion of patients presenting with motor symptoms was similar between those who
drink minimal amount of alcohol, those currently misusing alcohol and those who had
misused alcohol in the past (37.2%, 41.2% and 40.2% respectively). However, those who
are currently misusing alcohol, or had misused it in the past, were more likely to have a
psychiatric symptom identified as their initial clinical feature first (55.3% and 30.7%) by
comparison with those who do not drink excessively (4.9%).
3.3. The Effect of Alcohol on HD Severity
In addition to age at onset of disease, severity of HD was also influenced by alcohol
(Figure 1). The average total motor score of UHDRS in the control group was lower (27)
compared with patients who reported alcohol problems in the past (29) and the difference
was statistically significant (Kruskal–Wallis, post hoc Dunn’s, p < 0.001).
The MMSE tool was used as a simple screen for cognitive impairment, with scores of
below 24 defining a dementia. [19]. By contrast to motor symptoms, patients who reported
past problems with alcohol did not have a significantly lower MMSE score (26) compared
with control group (26, Kruskal–Wallis, post hoc Dunn’s, p > 0.05, Figure 1). There was also
no difference between those who used high levels of alcohol at the time of the study and
the control group (27 and 26 respectively, Kruskal–Wallis, post hoc Dunn’s, p > 0.05).
As for the PBA components of depression, irritability, psychosis, apathy and executive
function, patients who had a prior history of alcohol abuse had higher scores (indicating
greater burden) in all these domains when compared with the control group. However,
this was not the case for patients currently drinking excessively (Figure 2, Kruskal–Wallis,
post hoc Dunn’s, p < 0.01).
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Having previously never had a problematic relationship with alcohol use, she was 
described by her family as displaying stereotyped drinking behaviour that started in the 
early evening with beer and was followed by wine, white then red. They were unable to 
dissuade her from drinking in this way or from several other compulsive behaviours, 
which included habitual checking and extreme cleanliness. 
Prior to her HD diagnosis, she only drank alcohol on social occasions, and very 
rarely consumed alcohol at home. There was no history of other recreational drug use or 
psychiatric illness. An escalation in confused aggression and impulsive behaviour and 
Figure 2. Problem Behaviours Assessments (PBAs) as a measure of psychiatric burden in Huntington’s Disease (HD) shows
depression, apathy, irritability, psychosis and executive function are all significantly more sever when compared to controls
(Kruskal Wallis, post hoc Dunn’s, p < 0.0001). p values <0.01 shown as ‘**’ and p <0.001 as ‘***’.
3.4. Case Vignette
Our patient had a positive predictive genetic test for HD (CAG repeat lengths: >39,
32) at age 37, which was some years after her father had been diagnosed with the condition.
Premorbidly, her personality had been quiet and shy. She lived with her husband and two
children, both younger than 18 at the time of the predictive test.
Following her first neurology outpatient appointment at 45, she developed increasing
impulsivity but also complusive behaviour and only mild motor impairment. Having
previously never had a problematic relationship with alcohol use, she was described by
her family as displaying stereotyped drinking behaviour that started in the early evening
with beer and was followed by wine, white then red. They were unable to dissuade her
from drinking in this way or from several other compulsive behaviours, which included
habitual checking and extreme cleanliness.
Prior to her HD diagnosis, she only drank alcohol on social occasions, and very
rarely consumed alcohol at home. There was no history of other recreational drug use
or psychiatric illness. An escalation in confused aggression and impulsive behaviour
and increasing risk of falls while intoxicated led to emergency admission for psychiatric
assessment and treatment. Following this admission of several weeks, her routines changed.
Alcohol was no longer the focus of her compulsions, but rather patterns of taking exercise.
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Her family noted a major, enduring improvement in HD impairments in all three domains
of motor function, psychiatric disturbance and cognition.
4. Discussion
We describe a specific patient with HD for whom obsessional traits were key both
to the development and resolution of alcohol misuse. Of course, psychological distress
from the fact of a diagnosis of progressive neurological disease and from awareness of
neurological impairment will have been additional contributors. In our patient, direct
effects of alcohol intoxication severely compounded neuropsychiatric and motor symptoms
from the genetically confirmed dementing neurodegenerative disease. Triggered by our
experience of this case, we took the opportunity of interrogating the global Enroll-HD
database for any relationship between alcohol intake, previous or current, and clinical
features in HD.
While we found that alcohol misuse in HD as a problem in a significant minority
of the HD population, specific patterns were difficult to elucidate despite the very clear
categories used for the analysis and the very large sample at our disposal. The Enroll-HD
data included substantially more patients who had a past history of problem alcohol use
than those who were drinking heavily at the time of their Enroll HD assessment. Of the
three domains of HD symptom, psychiatric symptoms occurred on average at the earliest
age on average, followed by motor and then cognitive symptoms. As the diagnosis of
manifest HD for practical purposes is made at the onset of motor symptoms, these early
psychiatric features are inferred to have been prodromal, i.e., occurring before manifest
HD is diagnosed [1]. For those patients who had a prior history of problem alcohol use,
the age at onset of HD was not significantly earlier. Neither were those who were drinking
greater than 30 units at time of assessment diagnosed with HD at a significantly earlier
age. However, a potential limitation here is not knowing when the problem alcohol use
occurred in relation to age of onset of symptoms.
By contrast with the lack of association of excessive alcohol intake on HD onset, HD
severity profile, as measured by the UHDRS total motor score, was shown to be worse in
those with documented previous problem alcohol use. Overall, patients with a history of
alcohol use had a higher burden of impairment as measured by UHDRS and the PBAs, but
not the MMSE (Figure 1). Although the MMSE is widely used as a dementia screening
tool, its ability detect incremental changes in cognition is limited. Ongoing high levels of
alcohol use did not, on the other hand, appear to correlate with increased burden or an
earlier age of onset of HD. Of note, acute alcohol intoxication can cause many symptoms
that could mimic those of HD such as poor attention and concentration, changes to mood,
imbalance and falls. Our data do not show whether neurological impairment was a factor
that may have led to curtailment of alcohol use. Alcohol appeared to influence some
psychiatric symptoms more than others, specifically depression and irritability. Whether
these symptoms are more common comorbidities or more common as a consequence of
alcohol is not something that was looked at specifically in this study. The role of alcohol
in psychiatric symptoms in particular is a well-known phenomenon, that appears to also
apply to HD patients.
Within the PBA there are a number of psychiatric symptoms evaluated, including
depression, irritability and apathy as mentioned above. Psychosis and other obsessional
symptoms (described as executive function) are within the assessment. The increase in
burden of symptoms is conserved across these domains and are not limited to common
psychiatric complaints, such as depression. The overall increase in burden of each of these
symptoms in patients who have historically abused alcohol, but not in those that currently
abuse alcohol, was unexpected.
The correlation between a past problem alcohol use and the increase in the degree
of impairment does not give a clear answer as to causation. A history of heavy alcohol
use was more common in those patients who had manifest disease (1460 compared to 222).
Could this perhaps suggest that patients are curbing their drinking to stop the deterioration
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of symptoms? Further investigation is needed to elucidate the contributing factors to
patients’ cessation of high alcohol intake.
The main limitations to this study relate to the covariates to clinical HD presentation,
including CAG repeat length, as well as the use of MMSE as a cognitive assessment score.
Age, CAG repeat length, total motor score and aspects of cognitive assessment can all be
used to help guide expected prognosis [20] but we were unable to include these co-variates
in the analysis. Furthermore, the detail concerning alcohol intake in this study is subject to
patient recall bias. In addition, high alcohol intake may be underrepresented in patients
who chose to engage with a research project, such as Enroll-HD. In making use of a large
dataset we are dependent on relatively simple measures, which is especially limiting in the
case of using MMSE as our only cognitive measure.
The relationship between current or prior excessive alcohol use and life expectancy is
question that could not usefully be addressed within the available follow-up period of the
data in our study and there is no specific literature on alcohol use in HD and effects on life
expectancy. In neurodegenerative conditions more generally, the picture is also complex.
In dementia and mild cognitive impairment (MCI), a low or moderate alcohol intake is
associated with longer life expectancy and has even been speculated to be protective,
whereas severe excess is prognostically unfavourable [15,21,22].
There is a significant minority of HD patients who reported a past history of alcohol
problems. Within this subset of patients, there was an increased burden of disease. These
results provide the clinician with an additional factor to address patients with problem
alcohol use; in particular to be aware of more frequent depression, irritability and apathy
and the value of counselling pre-manifest carriers of the HD genetic expansion about the
risk of high alcohol intake.
5. Conclusions
We have demonstrated clear instances of excess alcohol intake affecting well-being
in HD, both in a specific patient and within the Enroll-HD participants. Undoubtedly,
the combination of substance misuse and of this monogenetic neurodegenerative disease
adversely affects patients and their families. In our case report, the patient’s obsession was
important in the development of excess alcohol use and in its management, with consequent
improvement in clinical symptoms. The patient’s obsessionality was important in the
development of excess alcohol use and in its management, with consequent improvement
in clinical symptoms. Alcohol excess may be the most readily documented of all the forms
of recreational substance misuse harmful to the brain. The Huntington gene expansion is
very likely the most common individual genetic abnormality that leads to a dementing
illness, and in Enroll-HD is a unique global register for a specific neurodegenerative
dementia diagnosis. Despite the reality of substance use as a problem in dementia and
our focus on aspects which were relatively well-defined (namely alcohol as a substance
of misuse and the Enroll-HD database) the experiences of and ill-effects for individual
patients of substance misuse were too varied for specific patterns to be discerned. Alcohol
excess and misuse of other substances is likely to be an underestimated cause of harm in
HD, in other specific and rare neurodegenerative diseases and in the dementing diseases
more generally.
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